Toronto, Canada
Geneseeq Technology Inc. is a pioneering force in the field of precision oncology, leveraging next-generation sequencing (NGS) technologies to revolutionize cancer detection, diagnosis, and treatment. Operating from dual headquarters in Canada and China, the company upholds rigorous quality standards through its CAP-, CLIA-, and ISO 15189-accredited laboratories, and is certified ISO 13485 for both IVD and RUO kit development and manufacturing.
Founded in 2012, the company boasts a robust portfolio, including FDA-cleared and CE-IVD marked panels like GeneseeqPrime®. Its innovative offerings span pan-cancer panels, cancer-type-specific panels, MRD monitoring, and multi-cancer early detection solutions such as CanScan®, which enjoys FDA Breakthrough Device Designation. These products support over 8,000 oncologists globally and are integral to more than 2,700 research collaborations.
The company's most recent capital infusion—a CNY800.00M Series D round on 25 December 2019—involved key investors like Lilly Asia Ventures, SBCVC, and China Reform Holdings Corporation. Geneseeq’s innovative strides and commitment to enhancing precision cancer care affirm its leadership in the Biotechnology, Health Care, and Life Sciences sectors.
ACT Genomics
